KRAS G12C in mCRC (~3-4%): single-agent KRASG12C inhibitors insufficient (intrinsic EGFR...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-KRAS-G12C-CRC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-CRC |
| Sources | SRC-CIVIC SRC-ESMO-COLON-2024 SRC-NCCN-COLON-2025 |
Actionability Facts
| Biomarker | BIO-KRAS-G12C |
|---|---|
| Variant | G12C |
| Disease | DIS-CRC |
| ESCAT tier | IB |
| Recommended combinations | adagrasib + cetuximab, sotorasib + panitumumab |
| Contraindicated monotherapy | KRASG12C inhibitor monotherapy in CRC (analogous to BRAFi-monotherapy failure: EGFR-mediated reactivation) |
| Evidence summary | KRAS G12C in mCRC (~3-4%): single-agent KRASG12C inhibitors insufficient (intrinsic EGFR feedback). Combination adagrasib + cetuximab (KRYSTAL-1, Yaeger et al. NEJM 2023) ORR 46%, PFS 6.9 mo. Sotorasib + panitumumab (CodeBreaK 300, Fakih et al. NEJM 2023) ORR 26% vs investigator's choice. Both FDA-approved 2024. |
Notes
ESCAT IB. OncoKB Level 1. Combo with anti-EGFR antibody is mandatory. Frontline still FOLFOX/FOLFIRI ± bev.
Used By
No reverse references found in the YAML corpus.